• Product name
  • Description
    Rabbit polyclonal to CARD15
  • Specificity
    Ab47918 recognizes CARD15, a 1040 amino acid protein. Ab47918 also recognizes CARD15 alternatively spliced and mutated forms which contain the peptide immunogen sequence including CARD15 short, a 273 amino acid protein.
  • Tested applications
    Suitable for: WB, IP, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Cow, Chimpanzee
  • Immunogen

    Synthetic peptide:


    , corresponding to internal sequence amino acids 582-600 of Human CARD15 (NP 071445.1) and amino acids 35-53 of a short form (273 amino acids) of CARD15, (GenBank no. AAK70868.1.)

  • Positive control
    • Human tumor cell lines: PPC-1 (prostate carcinoma), NCI-H226 and NCI-H332M (lung carcinoma), SF-268 (glioblastoma), UO-31 and A498 (renal/kidney carcinoma), SK-MEL-5 and SK-MEL-28 (melanoma), and MCF-7 (breast carcinoma). Human colon tissue.


  • Form
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    Preservative: 0.05% Sodium Azide
    Constituents: Whole serum
  • Purity
    Whole antiserum
  • Clonality
  • Isotype
  • Research areas


Our Abpromise guarantee covers the use of ab47918 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
  • Application notes
    IHC-P: 1/1000 - 1/5000.
    IP: 1/50 - 1/200.
    WB: 1/1000 - 1/2000. Predicted molecular weight: 115 kDa. CARD15 produces, by alternative splicing, 13 different transcripts, all with introns, putatively encoding 13 different protein isoforms. Therefore, the molecular weights observed for CARD15 on Western blot may vary. Users are encoraged to go to the NCBI ACE View Data Base for more information about CARD15 isoforms: http://www.ncbi.nih.gov/IEB/Research/Acembly/

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Induces NF-kappa-B via RICK (CARDIAK, RIP2) and IKK-gamma. Confers responsiveness to intracellular bacterial lipopolysaccharides (LPS).
    • Tissue specificity
    • Involvement in disease
      Defects in NOD2 are the cause of Blau syndrome (BS) [MIM:186580]. BS is a rare autosomal dominant disorder characterized by early-onset granulomatous arthritis, uveitis and skin rash.
      Defects in NOD2 are a cause of susceptibility to inflammatory bowel disease type 1 (IBD1) [MIM:266600]. IBD1 is a chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.
      Defects in NOD2 are the cause of sarcoidosis early-onset (EOS) [MIM:609464]. EOS is a form of sarcoidosis manifesting in children younger than 4 years of age. Sarcoidosis is an idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved. Early-onset sarcoidosis is quite rare and has a distinct triad of skin, joint and eye disorders, without apparent pulmonary involvement. Compared with an asymptomatic and sometimes naturally disappearing course of the disease in older children, early-onset sarcoidosis is progressive and in many cases causes severe complications, such as blindness, joint destruction and visceral involvement.
    • Sequence similarities
      Contains 2 CARD domains.
      Contains 9 LRR (leucine-rich) repeats.
      Contains 1 NACHT domain.
    • Cellular localization
    • Information by UniProt
    • Database links
    • Alternative names
      • ACUG antibody
      • Arthrocutaneouveal granulomatosis antibody
      • BLAU antibody
      • CARD15 antibody
      • Caspase recruitment domain family, member 15 antibody
      • Caspase recruitment domain protein 15 antibody
      • Caspase recruitment domain-containing protein 15 antibody
      • CD antibody
      • CLR16.3 antibody
      • IBD1 antibody
      • Inflammatory bowel disease protein 1 antibody
      • LRR containing protein antibody
      • NLR family, CARD domain containing 2 antibody
      • NLRC2 antibody
      • NOD like receptor C2 antibody
      • NOD2 antibody
      • NOD2 protein antibody
      • NOD2_HUMAN antibody
      • NOD2B antibody
      • nucleotide binding oligomerization domain 2 antibody
      • Nucleotide binding oligomerization domain containing 2 antibody
      • Nucleotide binding oligomerization domain, leucine rich repeat and CARD domain containing 2 antibody
      • Nucleotide-binding oligomerization domain-containing protein 2 antibody
      • PSORAS1 antibody
      see all

    Anti-CARD15 antibody images

    • All lanes : Anti-CARD15 antibody (ab47918) at 1/2000 dilution

      Lane 1 : PPC-1 (prostate carcinoma)
      Lane 2 : NCI-H226(lung carcinoma)
      Lane 3 : HOP-92
      Lane 4 : SF-268 (glioblastoma)
      Lane 5 : UO-31 (renal/kidney carcinoma)
      Lane 6 : A498 (renal/kidney carcinoma)
      Lane 7 : SK-MEL-5
      Lane 8 : SK-MEL-28 (melanoma)
      Lane 9 : MCF-7 (breast carcinoma)
      Lane 10 : Lymphoma. Lymphoma is from a cell line generated from a tumor growing in nude mice following injection of primary human lymphoma cells.

      Lysates/proteins at 30 µg per lane.

      Predicted band size : 115 kDa
    • Formalin-fixed, paraffin-embedded normal human colon stained for CARD15 expression using ab47918 at 1:2000.

      A, tissue core from a colon tissue microarray.

      A1, high magnification of A. Hematoxylin-eosin counterstain.

    References for Anti-CARD15 antibody (ab47918)

    ab47918 has not yet been referenced specifically in any publications.

    Product Wall

    There are currently no Abreviews or Questions for ab47918.
    Please use the links above to contact us or submit feedback about this product.


    Sign up